Evidence map›Paper›PMID 37328543›Full record

ArticleScientific reports2023

A missense variant at the RAC1-PAK1 binding site of RAC1 inactivates downstream signaling in VACTERL association.

Rie Seyama, Masashi Nishikawa, Yuri Uchiyama, Keisuke Hamada, Yuka Yamamoto, Masahiro Takeda, Takanori Ochi, Monami Kishi, Toshifumi Suzuki, Kohei Hamanaka and 13 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. A matter of switch: how RAC1 variants drive distinct disorders.European journal of human genetics : EJHG · 2026
    Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 7 institutions in 1 country.

Rie Seyama *Department of Human Genetics, Yokohama City University Graduate School of Medicine, Fukuura 3-9, Kanazawa-ku, Yokohama, 236-0004, Japan.
Masashi Nishikawa *Department of Molecular Neurobiology, Institute for Developmental Research, Aichi Developmental Disability Center, 713-8 Kamiya, Kasugai, Aichi, 480-0392, Japan.
Yuri UchiyamaDepartment of Human Genetics, Yokohama City University Graduate School of Medicine, Fukuura 3-9, Kanazawa-ku, Yokohama, 236-0004, Japan.
Keisuke HamadaDepartment of Biochemistry, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Yuka YamamotoDepartment of Obstetrics and Gynecology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Masahiro TakedaDepartment of Pediatric Surgery, Juntendo University School of Medicine, Tokyo, Japan.
Takanori OchiDepartment of Pediatric Surgery, Juntendo University School of Medicine, Tokyo, Japan.
Monami KishiDepartment of Human Pathology, Juntendo University School of Medicine, Tokyo, Japan.
Toshifumi SuzukiDepartment of Obstetrics and Gynecology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Kohei HamanakaDepartment of Human Genetics, Yokohama City University Graduate School of Medicine, Fukuura 3-9, Kanazawa-ku, Yokohama, 236-0004, Japan.
Atsushi FujitaDepartment of Human Genetics, Yokohama City University Graduate School of Medicine, Fukuura 3-9, Kanazawa-ku, Yokohama, 236-0004, Japan.
Naomi TsuchidaDepartment of Human Genetics, Yokohama City University Graduate School of Medicine, Fukuura 3-9, Kanazawa-ku, Yokohama, 236-0004, Japan.
Eriko KoshimizuDepartment of Human Genetics, Yokohama City University Graduate School of Medicine, Fukuura 3-9, Kanazawa-ku, Yokohama, 236-0004, Japan.
Kazuharu MisawaDepartment of Human Genetics, Yokohama City University Graduate School of Medicine, Fukuura 3-9, Kanazawa-ku, Yokohama, 236-0004, Japan.
Satoko MiyatakeDepartment of Human Genetics, Yokohama City University Graduate School of Medicine, Fukuura 3-9, Kanazawa-ku, Yokohama, 236-0004, Japan.
Takeshi MizuguchiDepartment of Human Genetics, Yokohama City University Graduate School of Medicine, Fukuura 3-9, Kanazawa-ku, Yokohama, 236-0004, Japan.
Shintaro MakinoDepartment of Obstetrics and Gynecology, Juntendo University Urayasu Hospital, Urayasu, Japan.
Takashi YaoDepartment of Human Pathology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Hidenori ItoDepartment of Molecular Neurobiology, Institute for Developmental Research, Aichi Developmental Disability Center, 713-8 Kamiya, Kasugai, Aichi, 480-0392, Japan.
Atsuo ItakuraDepartment of Obstetrics and Gynecology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Kazuhiro OgataDepartment of Biochemistry, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Koh-Ichi NagataDepartment of Molecular Neurobiology, Institute for Developmental Research, Aichi Developmental Disability Center, 713-8 Kamiya, Kasugai, Aichi, 480-0392, Japan. knagata@inst-hsc.jp.
Naomichi MatsumotoDepartment of Human Genetics, Yokohama City University Graduate School of Medicine, Fukuura 3-9, Kanazawa-ku, Yokohama, 236-0004, Japan. naomat@yokohama-cu.ac.jp.
Yokohama City University · JPJuntendo University · JPAichi Developmental Disability Center · JPJuntendo University Urayasu Hospital · JPKeiai University · JPNagoya University · JPRIKEN Center for Advanced Intelligence Project · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RAC1 at 7p22.1 encodes a RAC family small GTPase that regulates actin cytoskeleton organization and intracellular signaling pathways. Pathogenic RAC1 variants result in developmental delay and multiple anomalies. Here, exome sequencing identified a rare de novo RAC1 variant [NM_018890.4:c.118T > C p.(Tyr40His)] in a male patient. Fetal ultrasonography indicated the patient to have multiple anomalies, including persistent left superior vena cava, total anomalous pulmonary venous return, esophageal atresia, scoliosis, and right-hand polydactyly. After birth, craniofacial dysmorphism and esophagobronchial fistula were confirmed and VACTERL association was suspected. One day after birth, the patient died of respiratory failure caused by tracheal aplasia type III. The molecular mechanisms of pathogenic RAC1 variants remain largely unclear; therefore, we biochemically examined the pathophysiological significance of RAC1-p.Tyr40His by focusing on the best characterized downstream effector of RAC1, PAK1, which activates Hedgehog signaling. RAC1-p.Tyr40His interacted minimally with PAK1, and did not enable PAK1 activation. Variants in the RAC1 Switch II region consistently activate downstream signals, whereas the p.Tyr40His variant at the RAC1-PAK1 binding site and adjacent to the Switch I region may deactivate the signals. It is important to accumulate data from individuals with different RAC1 variants to gain a full understanding of their varied clinical presentations.

Indexed as

p21-Activated KinasesVena Cava, SuperiorAnal CanalBinding SitesEsophagusHeart Defects, CongenitalHedgehog ProteinsHumansInfant, NewbornKidneyLimb Deformities, CongenitalMalerac1 GTP-Binding ProteinSpineTracheaHedgehog Proteinsp21-Activated KinasesPAK1 protein, humanrac1 GTP-Binding ProteinRAC1 protein, human

Identifiers

PMID37328543
PMCPMC10275923
OpenAlexW4380985633

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.